Blog - Page 1065 of 5757

WednesdayApr 13, 2022 9:15 am

GreenBox POS (NASDAQ: GBOX) Releases Fourth Quarter and Full Year 2021 Results

On March 31, GreenBox POS released the financial results for the three months (“Q4 FY 2021”) and full year (“FY2021”) ended December 31, 2021 Company achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020 The Q4 FY2021 results build on Q3 2021 figures in which the company reported year-over-year growth in both transaction volume and revenues The financial figures were accompanied by a corporate update and expected prospects for 2022. On Thursday, March 31, at 4.30 PM Eastern, investors, stakeholders, and the general public heard about the progress that…

WednesdayApr 13, 2022 9:15 am

InnerScope Hearing Technologies Inc. (INND) Ends 2021 on Right Foot, Set for a Dominant 2022

Over 31 million Americans have hearing loss but don’t utilize a hearing aid, primarily due to prohibitively high costs In the last 5 years, U.S. Presidents and Congress has demonstrated a strong commitment to making hearing aids affordable to all, including pressure on the FDA to complete changes now InnerScope has aggressively grown its business model through two key acquisitions and new sales channels that should lend to significant revenue growth as new regulations are put in place More than 38 million Americans have some degree of hearing loss. Sadly, due mostly to prohibitively high costs, only about 20% of…

WednesdayApr 13, 2022 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”) CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there The study…

TuesdayApr 12, 2022 2:39 pm

QualityStocksNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New Director, CEO

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced that its board of directors has nominated Dr. David R. Richards, PhD, FIoD, FRSA, CPsych, as a new director and the company’s chief executive officer. Richards comes to the new positions with impressive experience, including serving in leadership roles at Nortel Networks' GM Global Data; GM Global Supercarriers; GM UK Switching; and Global ThinkQuest Champion at Oracle's Education Foundation. He has served as CEO of Ellis Jones Solicitors, executive director of…

TuesdayApr 12, 2022 1:03 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria's DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection…

TuesdayApr 12, 2022 12:46 pm

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) to Participate in Leading Cannabis Event

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that CEO Luis Merchan will be presenting at the upcoming Benzinga Cannabis Capital Conference. The event is scheduled for April 20–21, 2022, in Miami, Florida. Merchan’s presentation is slated to begin at 3:20 p.m. ET on April 20. In addition to Merchan’s presentation, members of Flora's management team will be scheduling one-on-one investor meetings throughout the day. The Benzinga Cannabis Capital Conference gathers together more than 1,000 of the top movers and shakers in the cannabis industry and offers an invaluable opportunity for…

TuesdayApr 12, 2022 12:39 pm

QualityStocksNewsBreaks – SPYR Inc.’s (SPYR) Applied Magix Exploring AI Applications for Inclusion into IoT Products

SPYR (OTCQB: SPYR) (dba SPYR Technologies) is a technology company whose subsidiary, Applied Magix Inc., develops and resells Apple(R) ecosystem compatible products in the growing multibillion-dollar smart home and connected car markets. The company today announced that Applied Magix is exploring AI applications for inclusion into its products. Also known as artificial intelligence, AI is the branch of computer science that aims to answer the question, “Can machines think?” – and the endeavor to replicate or simulate human intelligence in machines. “As part of our Secret Lab initiatives, AI frequently comes to the forefront of product development and how to…

TuesdayApr 12, 2022 12:26 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (“GBM”) Spotlight event on April 14, 2022. The chat is scheduled for 11:30 a.m. ET and will include CNS Pharmaceuticals management team members, including CEO John Climaco, along with opinion leader Samuel A. Goldlust, MD. The focus of the chat will be GBM and the work that CNS Pharmaceuticals is doing to advance Berubicin, its novel anthracycline and the first anthracycline to…

TuesdayApr 12, 2022 9:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments

Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients) Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need…

Site Search

Company Search